Related references
Note: Only part of the references are listed.Emerging treatment options for extraintestinal manifestations in IBD
Thomas Greuter et al.
GUT (2021)
Vedolizumab and Extraintestinal Manifestations in Inflammatory Bowel Disease
Jurij Hanzel et al.
DRUGS (2021)
Ustekinumab for Extra-intestinal Manifestations of Inflammatory Bowel Disease: A Systematic Literature Review
Lucas Guillo et al.
JOURNAL OF CROHNS & COLITIS (2021)
Factors influencing the outcome of vedolizumab treatment: Real-life data with objective outcome measurements
Orla Mader et al.
UNITED EUROPEAN GASTROENTEROLOGY JOURNAL (2021)
Effect of Ustekinumab on Extraintestinal Diseases in Refractory Crohn's Disease
Antonio Tursi et al.
JOURNAL OF CROHNS & COLITIS (2021)
How to Optimize Treatment With Ustekinumab in Inflammatory Bowel Disease: Lessons Learned From Clinical Trials and Real-World Data
Ana Gutierrez et al.
FRONTIERS IN MEDICINE (2021)
Reframing Immune-Mediated Inflammatory Diseases through Signature Cytokine Hubs
Georg Schett et al.
NEW ENGLAND JOURNAL OF MEDICINE (2021)
The impact of ustekinumab on extraintestinal manifestations of Crohn's disease: A post hoc analysis of the UNITI studies
Neeraj Narula et al.
UNITED EUROPEAN GASTROENTEROLOGY JOURNAL (2021)
The Impact of Vedolizumab on Pre-Existing Extraintestinal Manifestations of Inflammatory Bowel Disease: A Multicenter Study
Guilherme Piovezani Ramos et al.
INFLAMMATORY BOWEL DISEASES (2021)
Ustekinumab for Crohn's Disease: Results of the ICC Registry, a Nationwide Prospective Observational Cohort Study
Vince B. C. Biemans et al.
JOURNAL OF CROHNS & COLITIS (2020)
Articular manifestations in patients with inflammatory bowel disease treated with vedolizumab
Anastasia Dupre et al.
RHEUMATOLOGY (2020)
Effectiveness of Ustekinumab on Crohn's Disease Associated Spondyloarthropathy: Real-World Data from the Sicilian Network for Inflammatory Bowel Diseases (SN-IBD)
Fabio Salvatore Macaluso et al.
EXPERT OPINION ON BIOLOGICAL THERAPY (2020)
Effects of ustekinumab on spondylitis-associated endpoints in TNFi-naive active psoriatic arthritis patients with physician-reported spondylitis: pooled results from two phase 3, randomised, controlled trials
Philip S. Helliwell et al.
RMD OPEN (2020)
Retrospective Analysis of Safety of Vedolizumab in Patients With Inflammatory Bowel Diseases
Joseph Meserve et al.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2019)
Incidence of Arthritis/Arthralgia in Inflammatory Bowel Disease with Long-term Vedolizumab Treatment: Post Hoc Analyses of the GEMINI Trials
Brian G. Feagan et al.
JOURNAL OF CROHNS & COLITIS (2019)
Emergence of severe spondyloarthropathy-related entheseal pathology following successful vedolizumab therapy for inflammatory bowel disease
Sayam Dubash et al.
RHEUMATOLOGY (2019)
Extraintestinal manifestations in inflammatory bowel disease - epidemiology, genetics, and pathogenesis
Thomas Greuter et al.
EXPERT REVIEW OF GASTROENTEROLOGY & HEPATOLOGY (2019)
Long-term Clinical Effectiveness of Ustekinumab in Patients with Crohn's Disease Who Failed Biologic Therapies: A National Cohort Study
Claire Liefferinckx et al.
JOURNAL OF CROHNS & COLITIS (2019)
Three Multicenter, Randomized, Double-Blind, Placebo-Controlled Studies Evaluating the Efficacy and Safety of Ustekinumab in Axial Spondyloarthritis
Atul Deodhar et al.
ARTHRITIS & RHEUMATOLOGY (2019)
Peripheral disease contributes significantly to the level of disease activity in axial spondyloarthritis
Janneke J. de Winter et al.
RMD OPEN (2019)
The Expanding Therapeutic Armamentarium for Inflammatory Bowel Disease: How to Choose the Right Drug[s] for Our Patients?
Pieter Hindryckx et al.
JOURNAL OF CROHNS & COLITIS (2018)
Ustekinumab in the management of Crohn's disease: Expert opinion
Alessandro Armuzzi et al.
DIGESTIVE AND LIVER DISEASE (2018)
Effects of Vedolizumab Therapy on Extraintestinal Manifestations in Inflammatory Bowel Disease
Mark Fleisher et al.
DIGESTIVE DISEASES AND SCIENCES (2018)
The Association Between Arthralgia and Vedolizumab Using Natural Language Processing
Tianrun Cai et al.
INFLAMMATORY BOWEL DISEASES (2018)
Arthrits occurrence or reactivation under Vedolizumab treatment for inflammatory bowel disease. A four cases report
Daniel Wendling et al.
JOINT BONE SPINE (2018)
Clinical management of rheumatologic conditions co-occurring with inflammatory bowel diseases
Carla Felice et al.
EXPERT REVIEW OF CLINICAL IMMUNOLOGY (2018)
Extraintestinal Manifestations in Vedolizumab and Anti-TNF-Treated Patients With Inflammatory Bowel Disease
Marla C. Dubinsky et al.
INFLAMMATORY BOWEL DISEASES (2018)
Impact of vedolizumab therapy on extra-intestinal manifestations in patients with inflammatory bowel disease: a multicentre cohort study nested in the OBSERV-IBD cohort
S. Tadbiri et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2018)
An induction or flare of arthritis and/or sacroiliitis by vedolizumab in inflammatory bowel disease: a case series
G. Varkas et al.
ANNALS OF THE RHEUMATIC DISEASES (2017)
Efficacy and Safety of Vedolizumab for Induction of Remission in Inflammatory Bowel Disease-the Israeli Real-World Experience
Uri Kopylov et al.
INFLAMMATORY BOWEL DISEASES (2017)
Ustekinumab for Moderate to Severe Crohn's Disease and Its Extraintestinal Manifestations
Amandeep Singh et al.
AMERICAN JOURNAL OF GASTROENTEROLOGY (2017)
Clinical benefit of vedolizumab on articular manifestations in patients with active spondyloarthritis associated with inflammatory bowel disease
Ambrogio Orlando et al.
ANNALS OF THE RHEUMATIC DISEASES (2017)
The First European Evidence-based Consensus on Extra-intestinal Manifestations in Inflammatory Bowel Disease
Marcus Harbord et al.
JOURNAL OF CROHNS & COLITIS (2016)
Vedolizumab induction therapy for inflammatory bowel disease in clinical practice - a nationwide consecutive German cohort study
D. C. Baumgart et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2016)
The Real-World Effectiveness and Safety of Vedolizumab for Moderate-Severe Crohn's Disease: Results From the US VICTORY Consortium
Parambir S. Dulai et al.
AMERICAN JOURNAL OF GASTROENTEROLOGY (2016)
Extraintestinal Manifestations of Inflammatory Bowel Disease
Stephan R. Vavricka et al.
INFLAMMATORY BOWEL DISEASES (2015)
Management of Musculoskeletal Manifestations in Inflammatory Bowel Disease
Tejas Sheth et al.
GASTROENTEROLOGY RESEARCH AND PRACTICE (2015)
Review article: anti-adhesion therapies for inflammatory bowel disease
T. Lobaton et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2014)
Extraintestinal manifestations in a large series of Italian inflammatory bowel disease patients
Maddalena Zippi et al.
WORLD JOURNAL OF GASTROENTEROLOGY (2014)
Frequency and Risk Factors for Extraintestinal Manifestations in the Swiss Inflammatory Bowel Disease Cohort
Stephan R. Vavricka et al.
AMERICAN JOURNAL OF GASTROENTEROLOGY (2011)
Inflammatory bowel disease associated arthropathy
Sheila L. Arvikar et al.
CURRENT REVIEWS IN MUSCULOSKELETAL MEDICINE (2011)
The Natural History of Adult Crohn's Disease in Population-Based Cohorts
Laurent Peyrin-Biroulet et al.
AMERICAN JOURNAL OF GASTROENTEROLOGY (2010)
Efficacy and safety of certolizumab pegol plus methotrexate in active rheumatoid arthritis: the RAPID 2 study. A randomised controlled trial
J. Smolen et al.
ANNALS OF THE RHEUMATIC DISEASES (2009)
Ustekinumab, a human interleukin 12/23 monoclonal antibody, for psoriatic arthritis: randomised, double-blind, placebo-controlled, crossover trial
Alice Gottlieb et al.
LANCET (2009)
Infliximab for the treatment of pyoderma gangrenosum: a randomised, double blind, placebo controlled trial
TN Brooklyn et al.
GUT (2006)
Infliximab in the treatment of extra-intestinal manifestations of Crohn's disease
A Rispo et al.
SCANDINAVIAN JOURNAL OF RHEUMATOLOGY (2005)
Impact of race and ethnicity on inflammatory bowel disease
D Basu et al.
AMERICAN JOURNAL OF GASTROENTEROLOGY (2005)
The effect of infliximab on extraintestinal manifestations of Crohn's disease
I Kaufman et al.
RHEUMATOLOGY INTERNATIONAL (2005)
Share Paper
